ReviewFrontiers in oncology2026
Carcinoma of unknown primary (CUP) of the head and neck: state of the art and future perspectives.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in molecular oncology, head and neck cancer diagnosis still relies on anatomical site and histopathology. In up to 5% of metastatic cases, no identifiable primary tumor is found, defining carcinoma of unknown primary (CUP) and posing significant diagnostic and therapeutic challenges. We conducted a narrative review of the literature focusing on current diagnostic and treatment strategies for head and neck CUP, including imaging, viral biomarkers (HPV, EBV), minimally invasive procedures, and transoral robotic surgery (TORS). While TORS plays a dual role in diagnosis and treatment, a multidisciplinary approach of neck dissection, radiotherapy, and chemotherapy in high-risk patients, remains the cornerstone of management. Personalization is increasingly crucial in this comprehensive context, mainly involving treatment tailoring and radiotherapy planning, where limited evidence on field definition is available. Ongoing trials, such as UK FIND study, highlight the potential of targeted surgery to tailor and possibly reduce radiotherapy fields for better patient outcomes and improved quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.